# A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

> **NCT04064060** · PHASE3 · RECRUITING · sponsor: **Celgene** · enrollment: 665 (estimated)

## Conditions studied

- Myelodysplastic Syndromes (MDS)
- Beta-thalassemia
- Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT04064060
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-12
- **Primary completion:** 2028-05-12
- **Final completion:** 2028-05-12
- **Target enrollment:** 665 (ESTIMATED)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04064060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04064060, "A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04064060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*